Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Preparing word cloud

×

Search

Type in a keyword to search

Filter by last modified time
See new records

Current Facets and Filters

  • Funding Agency:NIDDK (facet)
  • Website Status : Ascending

Facets

Sort alphabetically | Sort by count

Recent searches

SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.

(last updated: Sep 3, 2019)

Physical Resource or Software Tool Software

643 Results - per page

Resource NameResource TypeDescriptionKeywordsResource IDProper CitationParent OrganizationRelated ConditionFunding AgencyRelationReferenceWebsite StatusAlternate IDsAlternate URLsOld URLs
OligoGenome Resource, data or information resource, resource, databaseThe Stanford Human OligoGenome Project hosts a database of capture oligonucleotides for conducting high-throughput targeted resequencing of the human genome. This set of capture oligonucleotides covers over 92% of the human genome for build 37 / hg19 and over 99% of the coding regions defined by the Consensus Coding Sequence (CCDS). The capture reaction uses a highly multiplexed approach for selectively circularizing and capturing multiple genomic regions using the in-solution method developed in Natsoulis et al, PLoS One 2011. Combined pools of capture oligonucleotides selectively circularize the genomic DNA target, followed by specific PCR amplification of regions of interest using a universal primer pair common to all of the capture oligonucleotides. Unlike multiplexed PCR methods, selective genomic circularization is capable of efficiently amplifying hundreds of genomic regions simultaneously in multiplex without requiring extensive PCR optimization or producing unwanted side reaction products. Benefits of the selective genomic circularization method are the relative robustness of the technique and low costs of synthesizing standard capture oligonucleotide for selecting genomic targets.oligonucleotide, genome, probe, coding region, oligonucleotide sequence, chromosomeSCR_006025( OligoGenome , RRID:SCR_006025)Stanford University; Stanford; California Doris Duke Clinical Foundation, Howard Hughes Medical Foundation, Liu Bie Ju Cha and Family Fellowship in Cancer, NCI, NHGRI, NIDDK, NLM, Reddere Foundation, Wang Family FoundationPMID:22102592Last checked downnlx_151422
Genotype-IBD Sharing Test Resource, software resource, software application, resourceSoftware package to test if a marker can account in part for the linkage signal in its region. There are two versions of the software: Windows and Linux/Unix.identical by descent, genotype, gene, genetic, genomic, unix, ms-windows, linux, linkage disequilibrium, linkage, associationSCR_006257( Genotype-IBD Sharing Test , RRID:SCR_006257)Vanderbilt University; Tennessee; USA NHGRI, NIDDK, Vanderbilt Diabetes Centerlisted by: Genetic Analysis SoftwarePMID:14872409Last checked downnlx_154133http://phg.mc.vanderbilt.edu/content/gist
George M. O'Brien Kidney Center at Yale Resource, disease-related portal, topical portal, resource, service resource, portal, access service resource, data or information resourceCenter that facilitates translational and clinical research that will advance the prevention and treatment of kidney diseases.kidney disease, clinical researchSCR_015294( George M. O'Brien Kidney Center at Yale , RRID:SCR_015294)Yale School of Medicine; Connecticut; USA kidney diseaseNIDDKlisted by: NIDDK Information NetworkLast checked down
George M. O'Brien Kidney Center at Yale Renal Physiology Core Resource, service resource, resource, core facility, access service resourceCore provides specialized services and training for assessing renal function in small animals at the level of single tubules in vitro and in vivo (e.g. micropuncture, microperfusion, and tubule-specific microdissection), the whole kidney (e.g. clearance studies in anesthetized animals, perfusion fixation for histology studies), and the intact organism (e.g. balance studies in metabolic cages, acute and chronic BP measurements).phenotyping assays, renal physiology, microperfusionSCR_015296( George M. O'Brien Kidney Center at Yale Renal Physiology Core , RRID:SCR_015296) Yale School of Medicine; Connecticut; USA , George M. O'Brien Kidney Center at Yale NIDDKlisted by: NIDDK Information NetworkLast checked down
Cystic Fibrosis Center University of Pittsburgh Resource, disease-related portal, topical portal, resource, service resource, portal, access service resource, data or information resourceResearch center whose goal is to understand and translate the basic mechanisms of cystic fibrosis. It uses the molecular and cell biology of CFTR, CFTR mutants, infection, and inflammation with the overall theme of translating preclinical science into clinical investigations.cystic fibrosis mechanism, cystic fibrosis translational research, cystic fibrosis researchSCR_015400( Cystic Fibrosis Center University of Pittsburgh , RRID:SCR_015400)University of Pittsburgh; Pennsylvania; USA Cystic FibrosisCystic Fibrosis Foundation Research Development Program, NIDDKlisted by: NIDDK Information NetworkLast checked down
New York Obesity Nutrition Research Center Resource, disease-related portal, topical portal, resource, service resource, portal, access service resource, data or information resourceObesity research center which provides access to core facilities, seminars, and collaborations for researchers.obesity research center, obesity portalSCR_015442( New York Obesity Nutrition Research Center , RRID:SCR_015442)Columbia University; New York; USA ObesityNIDDKlisted by: NIDDK Information NetworkLast checked down
Type 1 Diabetes - Rapid Access to Intervention Development Resource, service resource, resourceNOTE: The T1D-RAID program is not currently accepting applications. Cooperative program that makes available, on a competitive basis, NCI resources for the pre-clinical development of drugs, natural products, and biologics to facilitate translation to the clinic of novel, scientifically meritorious therapeutic interventions for type 1 diabetes and its complications. A partial listing of those services includes: high-throughput screening, studies in animal models, formulation, pharmacology and toxicology studies, and bulk substances acquisition. Requests to T1D-RAID are brief (20 pages or less), and should clearly outline the resources required to ready the proposed therapeutic agent for clinical trials. T1D-RAID should enable entry into the clinic of promising molecules that are not otherwise likely to receive an adequate and timely clinical test. T1D-RAID is designed to accomplish the tasks that are rate-limiting in bringing discoveries from the laboratory to the clinic. Once a project has been approved, NIDDKstaff interact directly with the Principal Investigator (PI). NCI contractors perform the T1D-RAID-approved tasks under the direction of NIDDKand NCI staff. The required tasks will vary from project to project. In some cases T1D-RAID will support only one or two key missing steps necessary to bring a compound to the clinic; in other cases it may be necessary to supply the entire portfolio of development requirements needed to file an IND. Examples of tasks that can be supported by T1D-RAID include, but are not limited to: * Definition or optimization of dose and schedule for in vivo activity * Development of pharmacology assays * Conduct of pharmacology studies with a pre-determined assay * Acquisition of bulk substance (GMP and non-GMP) * Scale-up production from lab-scale to clinical-trials lot scale * Development of suitable formulations * Development of analytical methods for bulk substances * Production of dosage forms * Stability assurance of dosage forms * Range-finding initial toxicology * IND-directed toxicology, with correlative pharmacology and histopathology * Planning of clinical trials * Regulatory affairs, so that FDA requirements are likely to be satisfied by participating investigators seeking to test new molecular entities in the clinic * IND filing advice The output of T1D-RAID activities will be both products and information that will be made fully available to the originating investigator for support of an IND application and clinical trials. T1D-RAID does not sponsor clinical trials.therapeutic, drug, drug development, pharmacogenomicsSCR_000203( Type 1 Diabetes - Rapid Access to Intervention Development , RRID:SCR_000203)NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases Type 1 diabetesNCI, NIDDKrelated to: Type 1 Diabetes Preclinical Testing Program, listed by: NIDDK Information Network, submitted by: NIDDK Information NetworkLast checked downnlx_152742
Trans-Institute Angiogenesis Research Program Resource, portal, topical portal, resource, data or information resourceTrans-NIH program encouraging and facilitating the study of the underlying mechanisms controlling blood vessel growth and development. Other aims include: to identify specific targets and to develop therapeutics against pathologic angiogenesis in order to reduce the morbidity due to abnormal blood vessel proliferation in a variety of disease states; to better understand the process of angiogenesis and vascularization to improve states of decreased vascularization; to encourage and facilitate the study of the processes of lymphangiogenesis; and to achieve these goals through a multidisciplinary approach, bringing together investigators with varied backgrounds and varied interests.blood vessel, growth, development, target, therapeutic, vascularization, angiogenesis, lymphangiogenesisSCR_000384( Trans-Institute Angiogenesis Research Program , RRID:SCR_000384)National Institutes of Health Angiogenesis, LymphangiogenesisJDRF, NCI, NEI, NHLBI, NICHD, NIDDK, NINDSlisted by: NIDDK Information Network, submitted by: NIDDK Information NetworkLast checked downnlx_152866
NIDDK Inflammatory Bowel Disease Genetics ConsortiumResource, resource, biomaterial supply resource, data set, cell repository, material resource, data or information resourceRepository of biospecimen and phenotype data collected from Crohn's disease and ulcerative colitis cases and controls recruited at six sites throughout North America that are available to the scientific community. Phenotyping is performed using a standardized protocol, and lymphoblastoid cell lines are established for each subject. Phenotype data for each subject are collected by the Consortium's Data Coordinating Center (DCC), and phenotype data for all subjects with DNA samples are available. The resulting DNA samples have already been utilized by the Consortium to complete various association studies, including genome-wide association studies using dense genotyping arrays. Researchers can obtain DNA samples and phenotype, genotype, and pedigree data through the Data Repository. GWAS data must be requested through dbGAP. The IBDGC is involved with independent genetic research studies and actively works with members of the IBD and genetic communities on collaborative projects. They are also members of the International IBD Genetics Consortium. Phenotype Tools: The Consortium Phenotype Committee, led by Dr. Hillary Steinhart designed and validated paper forms to collect extensive phenotype data on Crohn's Disease and ulcerative colitis. Consortium phenotype tools are available for use by non-Consortium members.dna, cell line, serum, lymphocyte, lymphoblastoid cell line, gene, loci, genetic analysis, blood, phenotype, genome-wide association study, genotype, pedigree, metadata standard, genotyping arraySCR_001461(NIDDK Inflammatory Bowel Disease Genetics Consortium, RRID:SCR_001461)Yale School of Medicine; Connecticut; USA Inflammatory Bowel Disease, Crohn's disease, Ulcerative colitis, Control, Family memberNIDDKuses: NCBI database of Genotypes and Phenotypes, listed by: One Mind Biospecimen Bank Listing, NIDDK Information NetworkLast checked downnlx_152706https://www.niddkrepository.org/niddk/jsp/public/dataset.jsp#IBD
Teen-Longitudinal Assessment of Bariatric Surgery Resource, disease-related portal, topical portal, resource, research forum portal, portal, data or information resourceConsortium made up of five clinical centers and a data coordinating center facilitating coordinated clinical, epidemiological, and behavioral research in the field of adolescent bariatric surgery, through an observational study protocol for uniform data collection pre-operative, at surgery, and through 2 years post-operative at participating centers performing bariatric surgery on teenagers. The use of standardized definitions and data-collection instruments for sequential patients scheduled for surgery at each site will yield meaningful evidence-based recommendations for patient evaluation, selection, and follow-up care. In addition to investigating surgical outcomes, another broader goal of Teen-LABS is to better understand the etiology, pathophysiology, and behavioral aspects of severe obesity in youth and how this condition affects human beings over time. The Teen-LABS consortium members include: Cincinnati Children's Hospital Medical Center, Texas Children's Hospital, Children's Hospital of Alabama, University of Pittsburgh, Nationwide Children's Hospitaladolescent human, bariatrics, pre-operative, at surgery, post-operative, clinical, epidemiology, behavior, surgical outcome, metadata standard, observational study, clinical, experimental protocol, evidence-based recommendation, patient evaluation, follow-up careSCR_001492( Teen-Longitudinal Assessment of Bariatric Surgery , RRID:SCR_001492)Bariatric surgery, ObesityNIDDKlisted by: NIDDK Information Network, submitted by: NIDDK Information NetworkLast checked downnlx_152747
Look AHEAD Resource, resource, clinical trial16-center, randomized clinical trial investigating the long-term health consequences of an intensive lifestyle intervention program designed to achieve and maintain weight loss by decreased caloric intake and increased physical activity in overweight volunteers with type 2 diabetes. The Look AHEAD cohort comprises approximately 5,000 overweight or obese participants with type 2 diabetes, aged 45-76. Participants were randomized to one of two interventions: an intensive lifestyle intervention designed to produce and sustain weight loss over the long term or a diabetes support and education arm. Participants will be followed for a total of 11 to 13.5 years from randomization. The primary hypothesis is that the incidence rate of the first post-randomization occurrence of a composite outcome, which includes * cardiovascular death (including fatal myocardial infarction and stroke), * non-fatal myocardial infarction, * hospitalized angina, and * non-fatal stroke, over a planned follow-up period of up to 13.5 years will be reduced among participants assigned to the Lifestyle Intervention compared to those assigned to the control condition, Diabetes Support and Education. Look AHEAD will also test for reductions in the incidence of three secondary composite outcomes and examine the effect of the intervention on cardiovascular disease risk factors, diabetes control and complications, general health, and quality of life, and psychological outcomes. The cost and cost-effectiveness of the Lifestyle Intervention relative to Diabetes Support and Education will be assessed. The Look AHEAD intensive lifestyle intervention ended September, 2012. Participants continue to be followed to determine the long-term effects of the intervention on health outcomes.weight loss, caloric intake, physical activity, health outcome, long-term effect, longitudinal, intervention, late adult human, middle adult human, cardiovascular disease, risk factor, diabetes control, diabetes complication, health, quality of life, psychological outcome, clinicalSCR_001490( Look AHEAD , RRID:SCR_001490)Wake Forest University; North Carolina; USA Type 2 diabetes, Overweight, ControlNIDDKlisted by: NIDDK Information Network, submitted by: NIDDK Information NetworkLast checked downnlx_152745https://www.lookaheadtrial.org/public/home.cfm
Adult to Adult Living Donor Liver Transplantation Cohort Study Resource, disease-related portal, topical portal, resource, research forum portal, portal, data or information resourceStudy consisting of nine liver transplant centers with expertise in adult living-donor liver transplantation (LDLT) and a central data coordinating center to provide valuable information on the outcomes of adult to adult living donor liver transplantation (AALDLT) to aid decisions made by physicians, patients, and potential donors. The study will establish and maintain the infrastructure required to accrue and follow sufficient numbers of patients being considered for and undergoing AALDLT to provide generalizable data from adequately powered studies. The major aims of A2ALL are as follows: * Quantify the impact of choosing LDLT on the candidate for transplantation * Characterize the difference between LDLT and deceased donor liver transplant (DDLT) in terms of post-transplant outcomes, including patient and graft survival, surgical morbidity, and resource utilization on the recipient of a transplant * Determine the short- and long-term health and quality of life (QOL) impact of donation, including (a) morbidity after liver donation and (b) long-term health-related QOL of donors. * Standardize and assess the role of informed consent in affecting the decision to donate and satisfaction after living liver donation * Other aims include comparison of the severity of recurrence of hepatocellular carcinoma for DDLT versus LDLT, the systematic characterization of liver regeneration and function in donors and recipients, the evaluation of the differences in the immune response to LDLT versus DDLT, and the establishment of a robust data and sample repository on liver transplantation that may be used to study clinical and biological questions as new technologies and resources become available. Patients enrolled in the study will be followed and managed in a standardized fashion.transplant, liver, adult human, risk factor, surgery, outcome, quality of life, clinicalSCR_001494( Adult to Adult Living Donor Liver Transplantation Cohort Study , RRID:SCR_001494)University of Michigan; Michigan; USA Liver transplant, Liver diseaseNIDDKlisted by: NIDDK Information Network, submitted by: NIDDK Information NetworkReferences (3)Last checked downnlx_152749
Standardization of C-peptide measurements Resource, narrative resource, resource, standard specification, data or information resourceStandardization of c-peptide by calibrating C-peptide measurement to a reference method can increase comparability between laboratories. The C-peptide standardization program is supported to establish reliability in results and facilitate the conduct of international clinical trials. For c-peptide, purified or processed material shows significant matrix effects and cannot be used for calibration. The C-peptide program has evaluated the use of single donor and pooled specimens for use by manufacturers in the calibration of these assays and determined that this strategy will reduce C-peptide variability among different assay methods. The standardization process through manufacturer re-calibration is ongoing.c-peptide, insulin secretion, clinical, calibrationSCR_001499( Standardization of C-peptide measurements , RRID:SCR_001499)University of Missouri School of Medicine; Missouri; USA DiabetesNIDDKlisted by: NIDDK Information Network, submitted by: NIDDK Information NetworkPMID:18420730Last checked downnlx_152766
CKID A Prospective Cohort Study of Kidney Disease in Children Resource, disease-related portal, topical portal, resource, research forum portal, portal, bibliography, data or information resourceProspective, observational cohort study of children with mild to moderate chronic kidney disease (CKD) to: (1) determine risk factors for progression of pediatric chronic kidney disease (CKD); (2) examine the impact of CKD on neurocognitive development; (3) examine the impact of CKD on risk factors for cardiovascular disease, and; (4) examine the impact of CKD on growth. The CKiD study population will include a cohort of 540 children, age 1 16 years, expected to be enrolled over a 24-month period.child, young human, pediatric, risk factor, kidney function, neurodevelopment, cognitive ability, behavior, kidney, urologic problem, glomerular disease, adverse effect, cognition, growth, adolescent, infant, clinicalSCR_001500( CKID A Prospective Cohort Study of Kidney Disease in Children , RRID:SCR_001500)Johns Hopkins University; Maryland; USA Chronic kidney disease, Renal disease, Cardiovascular diseaseNCRR, NIDDKlisted by: NIDDK Information Network, submitted by: NIDDK Information NetworkLast checked downnlx_152790
Nonalcoholic Steatohepatitis Clinical Research Network Resource, disease-related portal, topical portal, resource, research forum portal, portal, clinical trial, data or information resourceClinical research network to focus on the etiology, contributing factors, natural history, complications, and therapy of nonalcoholic steatohepatitis. They research the nature and underlying cause of Nonalcoholic Steatohepatitis (NASH) and conduct clinical studies on prevention and treatment. Approximately 1,500 pediatric and adult participants throughout the United States and Canada with nonalcoholic fatty liver disease (NAFLD) have enrolled into a database. The NASH CRN has recently reopened the database to enroll additional pediatric and adult participants with NAFLD. Serum, liver tissue, and genomic DNA samples are being collected and stored in the NIDDKrepository for ongoing as well as future studies. A three-arm randomized, placebo-controlled clinical trial of pioglitazone versus vitamin E completed enrollment in 2009. In addition to this adult trial, a similar trial in pediatric NASH patients randomized 180 children to receive treatment with vitamin E, metformin, or placebo.prevention, treatment, pediatric, child, adult human, serum, liver tissue, dna, placebo, pioglitazone, vitamin e, metformin, etiology, contributing factor, natural history, complication, therapy, young human, database, clinical trial, bibliography, patient registrySCR_001519( Nonalcoholic Steatohepatitis Clinical Research Network , RRID:SCR_001519)Johns Hopkins University; Maryland; USA Nonalcoholic steatohepatitis, Nonalcoholic fatty liver diseaseNIDDKlisted by: One Mind Biospecimen Bank Listing, NIDDK Information Network, NIDDK Central Repository, submitted by: NIDDK Information NetworkLast checked downnlx_152845https://www.nashcrn.com
Drug-Induced Liver Injury Network Resource, disease-related portal, topical portal, resource, research forum portal, biomaterial supply resource, people resource, bibliography, portal, patient registry, material resource, clinical trial, data or information resourceProspective and retrospective registry of well-characterized cases of drug-induced liver disease. The goals of Network include the development of standardized procedures to identify and fully characterize bona fide cases of drug- and complementary and alternative medicines (CAM)-induced liver injury, and to conduct controlled, clinical studies that will include extensive collection of data, serum, DNA, and tissue specimens. Cases of liver injury due to herbal medications are also included. The network will also develop terminology and standardized definitions for DILI, and to develop causality assessment instruments that are sensitive, specific, and reproducible. DILIN is funded by a cooperative agreement and includes five clinical centers and a central data coordinating center. The research goals of DILIN are to: * Create a registry of carefully documented DILI cases * Identify clinical, immunological, and environmental risk factors for drug- and CAM-mediated hepatotoxicity * Create a bank of biological specimens consisting of DNA, plasma, and immortalized lymphocytes to facilitate detailed genetic analyses * Characterize the natural history of drug- and CAM-induced DILI for at least six months following enrollment * Develop the capability to recontact these individuals over an extended period of time so that additional studies exploring DILI mechanisms can be performed Two studies are being initiated by the network. In the Retrospective Study, the implicated drugs are restricted to isoniazid, phenytoin, combination clavulanic acid/amoxicillin, and valproic acid (Depakote), Nitrofurantoin, Trimethoprim-sulfamethoxazole, Minocycline, and Quinolone antibiotics. These drugs were chosen because they are frequently administered to patients not receiving other hepatotoxic drugs, making it easier to establish causality. Patients must be alive, and the date of onset of the DILI episode must be on or after January 1, 1994. In the Prospective Study, all incident cases of drug- and CAM-induced liver injury are being considered. Initial presentation to a healthcare professional must be within the previous six months. A detailed medication history of the implicated DILI drug together with all prescription, OTC, and herbal medications is being recorded. Liver and serological tests are being performed to characterize the injury and to exclude competing causes of liver injury. A blood sample is also being drawn for plasma storage and DNA isolation. These cases will be followed longitudinally to characterize the long-term effects of the DILI episode. For both studies, documented, clinically significant DILI must be recorded in the patient's medical charts so that a causal determination can be made. Patients will be excluded if they are unwilling or unable to provide a blood sample or participate in the genetics component. Children under two years of age at the time of enrollment are excluded due to blood-volume requirements. If you have patients who are eligible to participate in either study, please contact one the DILIN clinical sites. As a general policy, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites investigator-initiated research project applications for ancillary studies to ongoing, large-scale clinical trials, epidemiological studies, and disease databases supported by the Institute. These studies are focused on a wide range of diseases and conditions including diabetes, obesity, acute and chronic liver disease, chronic kidney disease, and benign prostatic hyperplasia, among others.prescription drug, over-the-counter drug, alternative medicine, herbal product, supplement, serum, dna, tissue, blood, immortalized lymphocyte, drug, medication, quinolone antibiotic, isoniazid, phenytoin, clavulanic acid, amoxicillin, valproic acid, depakote, nitrofurantoin, trimethoprim-sulfamethoxazole, minocycline, diagnosis, hepatotoxicity, risk factor, genetic analysisSCR_001524( Drug-Induced Liver Injury Network , RRID:SCR_001524)Duke University; North Carolina; USA Liver injury, Hepatic injury, Drug-induced liver diseaseNIDDKlisted by: One Mind Biospecimen Bank Listing, NIDDK Information Network, Diabetes Research Centers, submitted by: NIDDK Information NetworkLast checked downnlx_152822
Family Investigation of Nephropathy of Diabetes Resource, resource, clinical trialMulticenter observational study designed to identify genetic determinants of diabetic nephropathy. It is conducted in eleven U.S. clinical centers and a coordinating center, and with four ethnic groups (European Americans, African Americans, Mexican Americans, and American Indians). Two strategies are used to localize susceptibility genes: a family-based linkage study and a case-control study using mapping by admixture linkage disequilibrium (MALD). In the family-based study, probands with diabetic nephropathy are recruited with their parents and selected siblings. Linkage analyses will be conducted to identify chromosomal regions containing genes that influence the development of diabetic nephropathy or related quantitative traits such as serum creatinine concentration, urinary albumin excretion, and plasma glucose concentrations. Regions showing evidence of linkage will be examined further with both genetic linkage and association studies to identify genes that influence diabetic nephropathy or related traits. Two types of MALD studies are being done. One is a case-control study of unrelated individuals of Mexican American heritage in which both cases and controls have diabetes, but only the case has nephropathy. The other is a case-control study of African American patients with nephropathy (cases) and their spouses (controls) unaffected by diabetes and nephropathy; offspring are genotyped when available to provide haplotype data. The specific goals of this program: * Delineate genomic regions associated with the development and progression of renal disease(s) * Evaluate whether there is a genetic link between diabetic nephropathy and diabetic retinopathy * Improve outcomes * Provide protection for people at risk and slow the progression of renal disease * Help establish a resource for genetic studies of kidney disease and diabetic complications by creating a repository of genetic samples and a database * Encourage studies of the genetics of progressive renal diseasegenetic susceptibility, genetic pathway, renal, kidney, outcome, gene, genetics, european-american, african-american, mexican-american, american-indian, linkage association study, admixture linkage disequilibrium, mapping by admixture linkage disequilibrium, serum creatinine, urinary protein excretion, plasma glucose level, blood pressure, blood lipid level, trait, linkage, adult human, male, female, clinicalSCR_001525( Family Investigation of Nephropathy of Diabetes , RRID:SCR_001525)NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases NIDDKlisted by: ClinicalTrials.gov, NIDDK Information Network, submitted by: NIDDK Information NetworkPMID:15642484Last checked downnlx_152825
Frequent Hemodialysis Network Daily Trial Resource, resource, clinical trialRandomized controlled clinical trial to understand how increasing hemodialysis to six times a week from the standard of three times a week may result in improved heart health. Subjects were recruited from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 1 year. Subjects will be randomized to either conventional hemodialyis Daily HD delivered for at least 2.5 hours (typically 3 to 4 hours), 3 days per week, or to more frequent hemodialysis delivered for 1.5 - 2.75 hours, 6 days per week. The study has two co-primary outcomes: 1) a composite of mortality with the change over 12 months in left ventricular mass by magnetic resonance imaging, and 2) a composite of mortality with the change over 12 months in the SF-36 RAND physical health composite (PHC) quality of life scale. In addition, main secondary outcomes have been designated for each of seven outcome domains: 1) cardiovascular structure and function (change in LV mass), 2) health-related quality of life/physical function (change in the PHC), 3) depression/burden of illness (change in Beck Depression Inventory), 4) nutrition (change in serum albumin), 5) cognitive function (change in the Trail Making Test B), 6) mineral metabolism (change in average predialysis serum phosphorus), and 7) clinical events (rate of non-access hospitalization or death). Hypertension and anemia are also main outcome domains, but without designation of single first priority outcomes.hemodialysis, cardiovascular, kidney, heartSCR_001527( Frequent Hemodialysis Network Daily Trial , RRID:SCR_001527)NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases Hemodialysis, End Stage Renal DiseaseNIDDKrelated to: Frequent Hemodialysis Network Nocturnal Trial, listed by: ClinicalTrials.gov, NIDDK Information Network, submitted by: NIDDK Information NetworkReferences (3)Last checked downnlx_152828
HALT PKD Resource, resource, clinical trialConsortium established to design and implement clinical trials of treatments that might slow the progressive loss of renal function in Polycystic Kidney Disease (PKD). Two multicenter randomized, double-blind, placebo controlled clinical trials are running concurrently to study the efficacy of renin-angiotensin-aldosterone system blockade on the progression of cystic disease (kidney volume) and on the decline in renal function in autosomal dominant polycystic kidney disease (ADPKD). Study A is to study whether intensive ACE-I/ARB blockade decrease the progression of cystic disease compared to ACE-I monotherapy patients with early disease, relatively preserved renal function, and high-normal BP or hypertension. Study B is to study whether intensive ACE-I/ARB blockade as compared to ACE-I monotherapy slow the decline in kidney function, end-stage of renal disease, or death in the setting of standard blood pressure control in hypertensive patients with moderately advanced disease.treatment, renal function, lisinopril, placebo, telmisartan, male, female, adolescent, adult humanSCR_001529( HALT PKD , RRID:SCR_001529)Washington University School of Medicine in St. Louis; Missouri; USA Polycystic kidney disease, Autosomal dominant polycystic kidney diseaseNIDDKlisted by: ClinicalTrials.gov, NIDDK Information Network, NIDDK Research Resources, submitted by: NIDDK Information NetworkLast checked downnlx_152832http://www.pkd.wustl.edu/pkdtn/
HALT-C Trial Resource, bibliography, resource, clinical trial, data or information resourceMulti-center, randomized controlled study designed to determine if continuing interferon long term over several years will suppress the Hepatitis C virus, prevent progression to cirrhosis, prevent liver cancer and reduce the need for liver transplantation. Patient enrollment began in 2000 and was completed in 2003 at 10 clinical centers, which were supported by a data coordinating center, virological testing center, and central sample repository. Patients with chronic hepatitis C and advanced fibrosis or cirrhosis on liver biopsy who failed to respond to a previous course of interferon alfa were enrolled in this study. Patients were initially treated with a 24-week course of peginterferon alfa-2a and ribavirin. Patients who remained hepatitis C virus RNA positive were then randomized to receive maintenance, low-dose peginterferon or to be followed on no treatment. Liver biopsies were done before enrollment and after 2 and 4 years of treatment or follow-up. The endpoints were development of cirrhosis, hepatic decompensation, hepatocellular carcinoma, death, or liver transplantation. 1050 patients were randomized and followed through the 4 year randomized phase of the trial and as long as 4 years off treatment. Serum samples collected at multiple time points, DNA and liver tissue are available for scientific investigation.interferon, progression, cirrhosis, prevention, liver cancer, liver transplantation, liver, pegylated interferon, clinical, outcome, adult human, dna, liver tissue, serum, blood, b lymphoblastoid cell-line, epstein-barr virus infection in peripheral blood mononuclear cell, peripheral blood mononuclear cell, biomaterial supply resource, formalin fixed, histology, frozen, stained liver slide, unstained liver slide, advanced fibrosis, liver biopsy, peginterferon alfa-2a, ribavirinSCR_001534( HALT-C Trial , RRID:SCR_001534)Hepatitis C virus, Chronic hepatitis CNIDDKlisted by: One Mind Biospecimen Bank Listing, ClinicalTrials.gov, NIDDK Central Repository, NIDDK Research Resources, NIDDK Information Network, submitted by: NIDDK Information NetworkLast checked downnlx_152835http://www.haltctrial.org/
X
  1. RRID Portal Resources

    Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.

  2. Navigation

    You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.

  3. Logging in and Registering

    If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.

  4. Searching

    Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:

    1. Use quotes around phrases you want to match exactly
    2. You can manually AND and OR terms to change how we search between words
    3. You can add "-" to terms to make sure no results return with that term in them (ex. Cerebellum -CA1)
    4. You can add "+" to terms to require they be in the data
    5. Using autocomplete specifies which branch of our semantics you with to search and can help refine your search
  5. Collections

    If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.

  6. Facets

    Here are the facets that you can filter the data by.

  7. Further Questions

    If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.